Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026)
Exelixis (EXEL) posted quarterly Change in Acquisitions & Divestments of $225.1 million for Q2 2026, down 13.05% year-over-year from $258.9 million in Q2 2025, and up 18.9% quarter-over-quarter from $189.3 million in Q1 2026.
Analysis
Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Exelixis' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $225.1 million for Q2 2026.
- In Q2 2026, Change in Acquisitions & Divestments fell 13.05% year-over-year to $225.1 million; the TTM figure through Apr 2026 stood at $989.1 million (up 13.98% YoY), while the FY2026 annual figure was $1.0 billion, up 16.59% from the prior year.
- Change in Acquisitions & Divestments for Q2 2026 stood at $225.1 million, up from $189.3 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $353.1 million in Q3 2025, with the low at $153.5 million in Q4 2023.
- The 5-year median for Change in Acquisitions & Divestments is $238.0 million (2022), against an average of $248.7 million.
- The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments sank 46.18% in 2024, then soared 64.02% in 2025.
- Exelixis' Change in Acquisitions & Divestments stood at $238.0 million in 2022, then sank by 35.5% to $153.5 million in 2023, then increased by 9.07% to $167.4 million in 2024, then jumped by 32.31% to $221.5 million in 2025, then grew by 1.63% to $225.1 million in 2026.
- Business Quant data shows EXEL's Change in Acquisitions & Divestments at $225.1 million in Q2 2026, $189.3 million in Q1 2026, and $221.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 169.27 Mn |
| Apr 3, 2026 | 225.13 Mn |
| Jan 2, 2026 | 189.34 Mn |
| Oct 3, 2025 | 221.51 Mn |
| Jul 4, 2025 | 353.10 Mn |
| Apr 4, 2025 | 258.92 Mn |
| Jan 3, 2025 | 226.16 Mn |
| Sep 27, 2024 | 167.42 Mn |
| Jun 28, 2024 | 215.28 Mn |
| Mar 29, 2024 | 268.45 Mn |
| Dec 29, 2023 | 153.49 Mn |
| Sep 29, 2023 | 311.08 Mn |
| Jun 30, 2023 | 263.14 Mn |
| Mar 31, 2023 | 310.77 Mn |
| Dec 30, 2022 | 237.99 Mn |
| Sep 30, 2022 | 326.41 Mn |
| Jul 1, 2022 | 232.74 Mn |
| Apr 1, 2022 | 267.62 Mn |
| Dec 31, 2021 | 282.70 Mn |
| Oct 1, 2021 | 381.73 Mn |